Quarterly report · Q2
2342.TEDINET S100PJSQ
Period2022-04-01 → 2022-09-30
Filed2022-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 48
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥5.5bn | 2022-04-01 → 2022-09-30 | Cons. | Net sales |
| Revenue | ¥12.6bn | 2021-04-01 → 2022-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥6.7bn | 2021-04-01 → 2021-09-30 | Cons. | Net sales |
| Operating income | ¥135m | 2022-04-01 → 2022-09-30 | Cons. | Operating income |
| Operating income | ¥1.6bn | 2021-04-01 → 2021-09-30 | Cons. | Operating income |
| Ordinary income | ¥204m | 2022-04-01 → 2022-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥1.8bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.5bn | 2021-04-01 → 2021-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥157m | 2022-04-01 → 2022-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥1.5bn | 2021-04-01 → 2021-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥55m | 2022-04-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥1.9bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥982m | 2021-04-01 → 2021-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥55m | 2022-04-01 → 2022-09-30 | Cons. | Profit loss |
| Net income | ¥976m | 2021-04-01 → 2021-09-30 | Cons. | Profit loss |
| Total assets | ¥10.7bn | at 2022-09-30 | Cons. | Assets |
| Total assets | ¥10.4bn | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥10.4bn | at 2021-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥4.0bn | at 2022-09-30 | Cons. | Liabilities |
| Total liabilities | ¥3.8bn | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥6.6bn | at 2022-09-30 | Cons. | Net assets |
| Net assets / equity | ¥6.6bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥5.9bn | at 2021-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥3.5bn | at 2022-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥4.6bn | at 2022-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥3.4bn | at 2022-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥4.6bn | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥3.4bn | at 2021-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥3.0bn | at 2021-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | −¥696m | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥1.8bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥883m | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥601m | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | ¥982m | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥238m | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | ¥65m | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥1.2bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥320m | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥3.26 | 2022-04-01 → 2022-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥4.79 | 2022-07-01 → 2022-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥109.52 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥56.56 | 2021-04-01 → 2021-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥21.52 | 2021-07-01 → 2021-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥109.31 | 2021-04-01 → 2022-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥56.4 | 2021-04-01 → 2021-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 60.8% | at 2022-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 62.6% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 55.4% | at 2021-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 31
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-09-30 | −¥2m |
| Reconciling Itemsreconciling | revenue external | 2022-04-01 → 2022-09-30 | ¥1m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-09-30 | −¥3m |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-09-30 | −¥111m |
| jpcrp040300-q2r_E05317-000Drug Discovery Support Businessreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥1.3bn |
| jpcrp040300-q2r_E05317-000Drug Discovery Support Businessreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥1.3bn |
| jpcrp040300-q2r_E05317-000Drug Discovery Support Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥3m |
| jpcrp040300-q2r_E05317-000Drug Discovery Support Businessreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥153m |
| jpcrp040300-q2r_E05317-000Investments And Consulting Businessreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥4.3bn |
| jpcrp040300-q2r_E05317-000Investments And Consulting Businessreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥4.3bn |
| jpcrp040300-q2r_E05317-000Investments And Consulting Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥187,000 |
| jpcrp040300-q2r_E05317-000Investments And Consulting Businessreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥92m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2022-09-30 | ¥5.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2022-09-30 | ¥5.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥3m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2022-09-30 | ¥246m |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2021-09-30 | −¥6m |
| Reconciling Itemsreconciling | revenue intersegment | 2021-04-01 → 2021-09-30 | −¥6m |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2021-09-30 | −¥97m |
| jpcrp040300-q2r_E05317-000Drug Discovery Support Businessreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥3.1bn |
| jpcrp040300-q2r_E05317-000Drug Discovery Support Businessreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥3.1bn |
| jpcrp040300-q2r_E05317-000Drug Discovery Support Businessreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥6m |
| jpcrp040300-q2r_E05317-000Drug Discovery Support Businessreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥1.6bn |
| jpcrp040300-q2r_E05317-000Investments And Consulting Businessreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥3.6bn |
| jpcrp040300-q2r_E05317-000Investments And Consulting Businessreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥3.6bn |
| jpcrp040300-q2r_E05317-000Investments And Consulting Businessreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥261,000 |
| jpcrp040300-q2r_E05317-000Investments And Consulting Businessreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥117m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-04-01 → 2021-09-30 | ¥6.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-04-01 → 2021-09-30 | ¥6.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥6m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-04-01 → 2021-09-30 | ¥1.7bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 513
| Item | Context | Value | Unit |
|---|---|---|---|
| Net increase decrease in cash and cash equivalents | Prior1YTDDuration | 324339000 | JPY |
| Net increase decrease in cash and cash equivalents | CurrentYTDDuration | -1223856000 | JPY |
| Cash and cash equivalents | Prior2YearInstant | 3030149000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 4618521000 | JPY |
| Cash and cash equivalents | Prior1QuarterInstant | 3354489000 | JPY |
| Cash and cash equivalents | CurrentQuarterInstant | 3394665000 | JPY |
| Salaries and allowances sga | Prior1YTDDuration | 234950000 | JPY |
| Salaries and allowances sga | CurrentYTDDuration | 229305000 | JPY |
| Retirement benefit expenses sga | Prior1YTDDuration | 1824000 | JPY |
| Retirement benefit expenses sga | CurrentYTDDuration | 2133000 | JPY |
| Provision for bonuses sga | Prior1YTDDuration | 37777000 | JPY |
| Provision for bonuses sga | CurrentYTDDuration | 28372000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E05317-000DrugDiscoverySupportBusinessReportableSegmentsMember | 3079735000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E05317-000InvestmentsAndConsultingBusinessReportableSegmentsMember | 3622394000 | JPY |
| Revenues from external customers | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 6702129000 | JPY |
| Revenues from external customers | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | Prior1YTDDuration | 6702129000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E05317-000DrugDiscoverySupportBusinessReportableSegmentsMember | 6000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E05317-000InvestmentsAndConsultingBusinessReportableSegmentsMember | 261000 | JPY |
| Transactions with other segments | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 6261000 | JPY |
| Transactions with other segments | Prior1YTDDuration_ReconcilingItemsMember | -6261000 | JPY |
| Transactions with other segments | Prior1YTDDuration | － | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E05317-000DrugDiscoverySupportBusinessReportableSegmentsMember | 3085735000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E05317-000InvestmentsAndConsultingBusinessReportableSegmentsMember | 3622655000 | JPY |
| Net sales | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 6708390000 | JPY |
| Net sales | Prior1YTDDuration_ReconcilingItemsMember | -6261000 | JPY |
| Net sales | Prior1YTDDuration | 6702129000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E05317-000DrugDiscoverySupportBusinessReportableSegmentsMember | 1582507000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E05317-000InvestmentsAndConsultingBusinessReportableSegmentsMember | 116579000 | JPY |
| Operating income | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 1699086000 | JPY |
| Operating income | Prior1YTDDuration_ReconcilingItemsMember | -96789000 | JPY |
| Operating income | Prior1YTDDuration | 1602297000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E05317-000DrugDiscoverySupportBusinessReportableSegmentsMember | 1265404000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E05317-000InvestmentsAndConsultingBusinessReportableSegmentsMember | 4275889000 | JPY |
| Revenues from external customers | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 5541293000 | JPY |
| Revenues from external customers | CurrentYTDDuration_ReconcilingItemsMember | 1050000 | JPY |
| Revenues from external customers | CurrentYTDDuration | 5542343000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E05317-000DrugDiscoverySupportBusinessReportableSegmentsMember | 3000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E05317-000InvestmentsAndConsultingBusinessReportableSegmentsMember | 187000 | JPY |
| Transactions with other segments | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 3187000 | JPY |
| Transactions with other segments | CurrentYTDDuration_ReconcilingItemsMember | -3187000 | JPY |
| Transactions with other segments | CurrentYTDDuration | － | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E05317-000DrugDiscoverySupportBusinessReportableSegmentsMember | 1268404000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E05317-000InvestmentsAndConsultingBusinessReportableSegmentsMember | 4276076000 | JPY |
| Net sales | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 5544481000 | JPY |
| Net sales | CurrentYTDDuration_ReconcilingItemsMember | -2137000 | JPY |
| Net sales | CurrentYTDDuration | 5542343000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E05317-000DrugDiscoverySupportBusinessReportableSegmentsMember | 153476000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E05317-000InvestmentsAndConsultingBusinessReportableSegmentsMember | 92063000 | JPY |
| Operating income | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 245539000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |